姑息放疗对体弱老年或转移性直肠腺癌的局部与症状控制评估
6个月局部控制率为46%(95%CI 33.6-59),1年为22.2%(95%CI 13-34.8);BED>37.5 Gy组症状控制显著优于低BED组(93.3% vs 55.6%,p=0.002),局部控制数值上更高但未达统计学显著(66.7% vs 33.3%,p=0.2)。
要点
- 6个月局部控制率46%,1年降至22.2%。
- BED>37.5 Gy组症状控制显著更优(p=0.002)。
- 30 Gy/10次方案症状控制亦显著更优(p=0.048)。
核心结论
- 较高BED与症状控制改善相关,局部控制呈非显著数值升高。
- 剂量升级包括大分割IMRT同步整合推量值得进一步评估。
研究设计与样本
- 中位年龄80岁,86%为T3-T4,54%伴转移。
- 主要终点为6个月局部控制,次要终点为症状缓解、总生存和毒性。
主要发现
- 中位随访13.3个月,6个月局部控制率46%(95%CI 33.6-59)。
- 1年局部控制率22.2%(95%CI 13-34.8)。
- 不同放疗方案间局部控制无显著差异。
- BED>37.5 Gy组局部控制66.7% vs 33.3%(p=0.2)。
- BED>37.5 Gy组症状控制93.3% vs 55.6%(p=0.002)。
关键数值与推荐
- BED>37.5 Gy与症状控制显著改善相关(93.3% vs 55.6%,p=0.002)。
- 30 Gy/10次方案与症状控制显著改善相关(92.3% vs 70%,p=0.048)。
- BED>37.5 Gy组局部控制66.7% vs 33.3%(p=0.2,未达显著)。
临床怎么用
- 对体弱老年或转移性直肠腺癌伴盆腔症状者,可考虑BED>37.5 Gy的姑息方案以改善症状控制。
- 30 Gy/10次方案可作为症状控制的候选方案之一。
- 局部控制仍不理想,需个体化权衡剂量升级与毒性。
局限性
- 不同放疗方案间比较非随机,可能存在混杂。
- BED>37.5 Gy组局部控制差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Locally advanced rectal cancer can cause severe pelvic symptoms (pain, hemorrhage, obstruction) in elderly, frail, or metastatic patients often unfit for surgery or optimal systemic therapy. The Swedish hypofractionated schedule (25 Gy in 5 fractions over 5 days) is widely used and effective in the neoadjuvant setting, but its role in palliation remains uncertain. Optimal dose and treatment duration remain to be defined. This study evaluates local and symptomatic control and treatment-related toxicity of different palliative irradiation schedules. MATERIALS AND METHODS: This retrospective study included patients treated with palliative radiotherapy for symptomatic, locally advanced, or metastatic rectal adenocarcinoma between 2010 and 2020 in five AP-HP Radiation Oncology departments. The primary endpoint was 6-month local control. Secondary endpoints were symptomatic response, overall survival, and toxicity. Survival was estimated using the Kaplan-Meier method and compared using log-rank test, categorical variables were compared using Fisher's exact test, and correlation using Spearman's coefficient. RESULTS: Sixty-three patients were included (median age of 80 years) with predominantly locally advanced disease (86% T3-T4), and frequent metastases (54%). With a median follow-up of 13.3 months, the local control was 46% at 6 months (95% CI: 33.6-59) and 22.2% at 1 year (95% CI: 13-34.8). Local control did not differ significantly between irradiation schedules but tended to be higher for BED >37.5 Gy (66.7% vs. 33.3%; p = 0.2). A statistically significant improvement in symptomatic control was observed for BED >37.5 Gy (93.3% vs. 55.6%; p = 0.002), and for the 30 Gy in 10 fractions schedule (92.3% vs. 70%; p = 0.048). Symptomatic and local control were correlated (p < 0.001). CONCLUSIONS: Higher BED was associated with improved symptomatic control and a non-significant numerical increase in local control compared with the Swedish schedule. Dose escalation, including hypofractionated IMRT using simultaneous integrated boost warrant further evaluation.
引用
- Bisson E, Nebbache R, Quéro L, et al. Local and symptomatic control evaluation in palliative radiotherapy for rectal adenocarcinoma in frail, elderly, or metastatic patients: a multicentric retrospective study. Clin Transl Radiat Oncol. 2026. PMID: 42569642. doi:10.1016/j.ctro.2026.101231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。